FUSN · Fusion Pharmaceuticals Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $2.01M | $34.0K | $28.0K | - | $166.0K | $570.0K | $585.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $21.31M | - | $14.59M | $18.99M | $15.88M | - | $16.55M | $12.08M | $12.66M | - |
| SG&A | $14.55M | - | $6.81M | $7.75M | $9.01M | - | $7.42M | $7.78M | $8.45M | - |
| Total Operating Expenses | $35.86M | - | $21.39M | $26.75M | $24.88M | - | $23.97M | $19.86M | $21.11M | - |
| D&A | $361.0K | - | - | - | $273.0K | - | - | - | $203.0K | - |
| Operating Income | ($35.86M) | - | ($19.39M) | ($26.71M) | ($24.86M) | - | ($23.80M) | ($19.29M) | ($20.52M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($237.0K) | - | ($253.0K) | ($245.0K) | ($11.0K) | - | ($761.0K) | ($681.0K) | ($55.0K) | - |
| Net Income | ($33.67M) | - | ($17.25M) | ($25.18M) | ($24.29M) | - | ($24.01M) | ($19.07M) | ($19.91M) | - |
| EPS - Basic | ($0.40) | - | ($0.25) | ($0.38) | ($0.45) | - | ($0.55) | ($0.44) | - | - |
| EPS - Diluted | ($0.40) | - | ($0.25) | ($0.38) | ($0.45) | - | ($0.55) | ($0.44) | - | - |
Balance Sheet
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.79M | $61.46M | $26.79M | $32.02M | $53.62M | $43.86M | $106.05M | $61.52M | $59.21M | $52.90M |
| Accounts Receivable | - | $7.0K | $41.0K | $62.0K | $89.0K | $61.0K | $215.0K | $177.0K | $325.0K | $357.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.50M | $1.86M | $1.06M | $2.06M | $1.90M | $2.69M | $1.31M | $1.55M | $1.77M | $2.19M |
| Current Assets | $220.92M | $243.40M | $203.26M | $207.86M | $220.62M | $179.00M | $215.85M | $207.07M | $204.78M | $211.76M |
| Total Assets | $323.81M | $285.84M | $253.38M | $268.29M | $266.55M | $219.06M | $238.49M | $228.13M | $235.96M | $252.27M |
| Current Liabilities | $20.76M | $16.22M | $17.48M | $17.09M | $17.32M | $15.07M | $13.41M | $11.58M | $12.18M | $12.51M |
| Long-term Debt | $49.69M | $34.77M | $34.63M | $34.49M | $34.36M | $34.23M | $34.11M | $9.63M | - | - |
| Total Liabilities | $81.98M | $63.36M | $64.91M | $65.33M | $65.72M | $56.84M | $55.35M | $29.23M | $20.53M | $20.82M |
| Stockholders' Equity | $241.83M | $222.48M | $188.47M | $202.96M | $200.83M | $162.22M | $246.50M | $198.91M | $215.43M | $231.46M |
| Retained Earnings | ($410.43M) | ($376.76M) | ($348.58M) | ($331.33M) | ($306.15M) | ($281.86M) | ($257.25M) | ($233.23M) | ($214.16M) | ($194.25M) |
Cash Flow
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($27.31M) | - | - | - | ($25.43M) | - | - | - | ($14.97M) | - |
| Investing Cash Flow | ($70.37M) | - | - | - | ($24.53M) | - | - | - | $19.13M | - |
| Financing Cash Flow | $64.01M | - | - | - | $59.52M | - | - | - | $1.71M | - |
| CapEx | $1.33M | - | - | - | $1.22M | - | - | - | $595.0K | - |
| Free Cash Flow | ($28.64M) | - | - | - | ($26.66M) | - | - | - | ($15.57M) | - |
Ratios
| Metric | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -966.6% | -78567.6% | -88767.9% | - | -14340.4% | -3383.7% | -3508.5% | - |
| EBITDA margin | - | - | - | - | -87792.9% | - | - | - | -3473.8% | - |
| Net margin | - | - | -860.0% | -74044.1% | -86753.6% | - | -14465.7% | -3346.1% | -3403.2% | - |
| Free cash flow margin | - | - | - | - | -95207.1% | - | - | - | -2660.9% | - |
| FCF / Net income | 0.85 | - | - | - | 1.10 | - | - | - | 0.78 | - |
| R&D / Revenue | - | - | 727.1% | 55864.7% | 56703.6% | - | 9970.5% | 2118.6% | 2164.3% | - |
| SG&A / Revenue | - | - | 339.5% | 22802.9% | 32164.3% | - | 4469.9% | 1365.1% | 1444.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.4% | - | -6.8% | -9.4% | -9.1% | - | -10.1% | -8.4% | -8.4% | - |
| Return on equity | -13.9% | - | -9.2% | -12.4% | -12.1% | - | -9.7% | -9.6% | -9.2% | - |
| Return on invested capital | -9.7% | - | -6.9% | -8.9% | -8.3% | - | -6.7% | -7.3% | - | - |
| Liquidity | ||||||||||
| Current ratio | 10.64 | 15.01 | 11.63 | 12.16 | 12.73 | 11.88 | 16.09 | 17.89 | 16.81 | 16.93 |
| Quick ratio | 10.64 | 15.01 | 11.63 | 12.16 | 12.73 | 11.88 | 16.09 | 17.89 | 16.81 | 16.93 |
| Cash ratio | 1.34 | 3.79 | 1.53 | 1.87 | 3.09 | 2.91 | 7.91 | 5.31 | 4.86 | 4.23 |
| Leverage | ||||||||||
| Debt / Equity | 0.21 | 0.16 | 0.18 | 0.17 | 0.17 | 0.21 | 0.14 | 0.05 | - | - |
| Debt / Assets | 0.15 | 0.12 | 0.14 | 0.13 | 0.13 | 0.16 | 0.14 | 0.04 | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.34 | 1.28 | 1.34 | 1.32 | 1.33 | 1.35 | 0.97 | 1.15 | 1.10 | 1.09 |
| Liabilities / Assets | 0.25 | 0.22 | 0.26 | 0.24 | 0.25 | 0.26 | 0.23 | 0.13 | 0.09 | 0.08 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.01 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | 7d | 666d | 1160d | - | 473d | 113d | 203d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | 1108.4% | -94.0% | -95.2% | - | -48.9% | 9.4% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -44.3% | - | 18.6% | -38.5% | -21.1% | - | -22.0% | 29.3% | -135.8% | - |
| Net income growth (YoY) | -38.6% | - | 28.2% | -32.0% | -22.0% | - | -23.6% | 29.0% | -13.6% | - |
| EPS growth (YoY) | 11.1% | - | 54.5% | 13.6% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -7.4% | - | - | - | -71.3% | - | - | - | -98.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 20.4% | 37.1% | -23.5% | 2.0% | -6.8% | -29.9% | 0.0% | -24.5% | -22.8% | -21.4% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Fusion Pharmaceuticals Inc. against the 5 most active filers in the same SIC group.